| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | pazopanib (Votrient®) |
| Formulation | 200 mg and 400 mg film-coated tablet |
| Reference number | 433 |
| Indication | Treatment of advanced renal cell carcinoma for patients who have received prior cytokine therapy for advanced disease |
| Company | GlaxoSmithKline |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 18/06/2010 |